52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Nanoviricides Says Data Shows Pan-Coronavirus Nanopviricide Drug Candidate NV-Cov-2-R Minimizes Loss Of Remdesivir To Bodily Metabolism
Gilead Sciences Reports Sub-Analysis Data From Breast Cancer Phase 3 Study
Galapagos H1 Net Loss Narrows To 55 Million Euros
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.
Biotechnology & Drugs
333 LAKESIDE DR
FOSTER CITY, CA
Chairman of the Board, Chief Executive Officer
Andrew D. Dickinson
Chief Financial Officer
Brett Alan Pletcher
Executive Vice President - Corporate Affairs, General Counsel, Company Secretary
Executive Vice President - Research
Chief Commercial Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
A U.S. appeals court on Thursday threw out a $1.2 billion ruling against Gilead Sciences Inc, finding a patent on a cancer therapy it was accused of infringing was invalid, in a blow to rival Bristol Myers Squibb Co.
Gilead Sciences Inc escaped a $1.2 billion fine, after the Federal Circuit Court of Appeals on Thursday found the relevant parts of a Bristol Myers Squibb patent that Gilead's Yescarta cancer drug allegedly infringed were invalid.
Gilead Sciences Inc said on Monday it will require all its employees and contractors in the United States to become vaccinated against COVID-19.
Gilead Sciences said on Thursday it has become aware that tampered and counterfeit versions of its HIV treatments, Biktarvy and Descovy, are in circulation within U.S. drug distribution networks.
Gilead Sciences Inc on Thursday posted a higher-than-expected second-quarter profit, helped by strong demand for its COVID-19 antiviral treatment, Veklury, but sales of its flagship HIV drugs lagged as the pandemic continued to limit visits to doctors.
Gilead Sciences Inc on Thursday posted higher second-quarter earnings, helped by strong sales of its COVID-19 antiviral treatment, Veklury, as well as hepatitis drugs.
The U.S. health regulator expanded the emergency use authorization for Eli Lilly's COVID-19 drug baricitinib, saying it could now be used without taking Gilead's drug remdesivir along with it, Lilly said on Thursday.
Federal authorities have seized at U.S. airports unauthorized versions of the COVID-19 treatment remdesivir destined for distribution in Mexico, the Wall Street Journal reported on Wednesday.
Gilead Sciences Inc said an analysis showed its antiviral remdesivir reduced mortality rates in hospitalized patients with COVID-19 and increased the likelihood of being discharged by day 28 after a five-day course of the treatment.
The European Medicines Agency (EMA) on Friday recommended extending conditional marketing approval by a year for Gilead Sciences' COVID-19 treatment, remdesivir, the only drug so far that has been authorized for use in the region.
Eli Lilly and Co said on Tuesday it would supply 400,000 tablets of its COVID-19 treatment, to be used with Gilead's remdesivir, to the Indian government as the country fights a raging pandemic that has morgues and hospitals overflowing.
Gilead Sciences Inc on Thursday reported first-quarter revenue that fell short of Wall Street estimates as the coronavirus pandemic hurt sales of its flagship HIV and hepatitis C drugs, partially offset by sales of COVID-19 antiviral treatment remdesivir.
Gilead Sciences Inc on Thursday said its first-quarter product sales rose 16%, including $1.46 billion in sales of its COVID-19 antiviral drug remdesivir, but sales of flagship HIV and hepatitis C drugs were down due to the effects of the pandemic.
U.S. drugmaker Merck & Co joined Gilead Sciences on Tuesday in lending support to India as the world's second-most populous country scrambles to address drug shortages and bring a raging new wave of COVID-19 cases under control.
Gilead Sciences Inc said on Monday it will provide support to new local manufacturing facilities in India and donate active pharmaceutical ingredient to scale up production of its COVID-19 drug, remdesivir. (https://refini.tv/2QqfmCn) (Reporting by Trisha Roy in Bengaluru...
Gilead Sciences Inc said on Monday it had decided to stop a late-stage trial of its intravenous treatment, Veklury, in high-risk non-hospitalized patients with COVID-19.
Gilead Sciences Inc and rival Merck & Co Inc said on Monday they will test a combination of their experimental HIV drugs to develop a long-acting treatment for the infection that affects millions worldwide.
Drug makers Gilead Sciences Inc and Merck & Co Inc are collaborating to develop a long-acting HIV therapy, the Wall Street Journal reported on Monday. (Reporting By Mrinalika Roy in Bengaluru; Editing by Shounak Dasgupta)
Europe's drugs regulator said on Tuesday it was expecting to give an opinion before the summer on whether Gilead Sciences' remdesivir can be used to treat COVID-19 patients who do not need oxygen support.
Europe's drugs regulator said on Tuesday it is evaluating the use of remdesivir in COVID-19 patients who do not need oxygen support, after developer Gilead Sciences submitted an application to extend the medicine's use.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.